Molecular Markers in Vascular Leiomyosarcomas

Share this content:
Prospective studies evaluating the clinical and therapeutic use of β-catenin and insulin-like growth factor 1 receptor should be performed.
Prospective studies evaluating the clinical and therapeutic use of β-catenin and insulin-like growth factor 1 receptor should be performed.

Prospective studies evaluating the clinical and therapeutic use of β-catenin and insulin-like growth factor 1 receptor in patients with vascular leiomyosarcomas should be performed, according to a study published in JAMA Surgery.1

Investigators conducted a retrospective medical record review of a cohort of patients with vascular leiomyosarcoma who presented to The University of Texas MD Anderson Cancer Center in Houston, TX, between January 1993 and April 2012. Their objective was to evaluate patient outcomes and the association between vascular leiomyosarcomas and immunohistochemical molecular markers to determine if there was any potential prognostic or therapeutic use.

Data were collected from 63 patients with localized disease who had undergone surgical resection. Median age at diagnosis was 58 years and 65% were female; 81% were white. Median time to local recurrence was 43 months, median time to distant recurrence was 25 months, and the median time to concurrent local and distant recurrences was 15 months (P = .04).

RELATED: TP53 Mutation Status Predictive of Pazopanib Response in Advanced Sarcomas

Results showed that strong presence of β-catenin (HR, 5.33; 95% CI, 0.97 – 29.30; P = .06) and insulin-like growth factor receptor 1 (HR, 2.74; 95% CI, 1.14 – 6.56; P = .02) were linked to poor disease-specific survival.

Reference

  1. Roland CL, Boland GM, Demicco EG, et al. Clinical observations and molecular variables of primary vascular leiomyosarcoma [published online ahead of print December 2, 2015]. JAMA Surg. doi: 10.1001/jamasurg.2015.4205.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters